Why Now: The Market Finally Caught Up to What Asher Set Out to Build

Three years ago, when Asher Informatics was founded, health system AI governance wasn't something CIOs had on their radar. At best, only leading academic medical center radiology and cardiology service lines were talking about it.

That has changed. Today, CIOs, clinical leaders, and compliance officers aren't asking whether they need AI governance. They're asking which solution meets the standard their organization can defend to a board, a regulator, or an auditor. That shift, from optional to expected, from a nice-to-have to a procurement requirement, is the market timing Asher was built around from day one.

That timing wasn't guesswork. It came from the insider access Asher had working alongside leading AI companies, watching the alternative already failing in the field. Health systems were piloting AI and struggling to move past it, not because the technology didn't work, but because they had no independent way to assess whether it was working or delivering real value. Leading AI vendors sales were already facing adoption, trust, and change management challenges hurdles. Vendor-generated reports on their own models weren't solving the problem. Clinicians don't trust a report card written by the company being graded.

FORGE™ exists because co-founder John Kalafut spent his career building regulated AI solutions and enterprise digital health solutions at his own consulting firm, GE Healthcare, and Bayer. Healthcare needed governance and quality assurance built by a party with no stake in which AI a health system chooses. From the beginning, Asher set out to connect governance controls with oversight and monitoring in one living AI management system. Earlier this year, FORGE™ moved from pilots to commercial release. Since then, the traction has moved well past general interest: health systems are requesting pricing, scoping details, and contract terms. There are budgets allocated for this solution, and health systems are willing to pay for it.

Governance and quality assurance for health and clinical AI must hold up under a different kind of scrutiny: audit trails, retrospective performance review, maturity modeling that a compliance officer can actually defend in front of a board. Building that kind of depth takes deep healthcare and clinical domain expertise, not just software engineering. That's what we’ve built, and it's what the traction to date has confirmed the market wants.

Meeting that level of demand is a different challenge than building a start-up. That's the traction behind Asher's leadership announcement today. Bringing in someone with a proven record of scaling commercial sales of new AI and digital health solutions, the kind of executive experience typically seen at the largest solution providers in this space, is a testament to the product and the maturity of the business. That caliber of leadership is brought in when the product has proven itself and the opportunity ahead is bigger than the team that built it.

Today, Asher named Aaron Sullivan as Chief Executive Officer, a change detailed in this morning's announcement. What every health system watching this space should take away is simpler than an org chart: the timing wasn't luck, and the traction wasn't a surprise. It was the market catching up to the problem Asher set out to solve, and the team now in place, with Aaron leading commercial growth, is built to solve it at the scale health systems expect.